Diarrhoea and oral mucositis caused by EGFR‐TKIs tend to occur later than nausea and emesis caused by platinum‐based drugs, and this may explain why the appetite‐related QOL was only affected at 6 weeks after initiating first‐line systemic therapy. The gene discussed is EGFR; the disease is oral mucositis.